Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of unusually large options trading on Tuesday. Stock investors acquired 111,741 call options on the stock. This represents an increase of 1,092% compared to the average volume of 9,376 call options.

Shares of NYSE TEVA opened at $15.93 on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 1.69. The firm has a market cap of $16.20 billion, a price-to-earnings ratio of 5.69, a P/E/G ratio of 3.01 and a beta of 1.34. Teva Pharmaceutical Industries has a 12-month low of $14.59 and a 12-month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. The business had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.57% and a negative net margin of 11.40%. The business’s revenue for the quarter was down 15.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.93 EPS. As a group, equities research analysts expect that Teva Pharmaceutical Industries will post 2.32 EPS for the current year.

In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 4,107 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $69,326.16. Following the transaction, the insider now directly owns 2,941 shares in the company, valued at approximately $49,644.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total value of $25,795.10. Following the transaction, the vice president now owns 13,469 shares in the company, valued at $211,463.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,334 shares of company stock worth $309,253. Company insiders own 0.43% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rehmann Capital Advisory Group boosted its position in shares of Teva Pharmaceutical Industries by 8.8% in the 3rd quarter. Rehmann Capital Advisory Group now owns 9,814 shares of the company’s stock worth $211,000 after purchasing an additional 795 shares in the last quarter. Hancock Whitney Corp boosted its position in shares of Teva Pharmaceutical Industries by 7.8% in the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock worth $186,000 after purchasing an additional 868 shares in the last quarter. Financial Counselors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.7% in the 4th quarter. Financial Counselors Inc. now owns 124,805 shares of the company’s stock worth $1,924,000 after purchasing an additional 872 shares in the last quarter. Hartford Investment Management Co. boosted its position in shares of Teva Pharmaceutical Industries by 3.1% in the 4th quarter. Hartford Investment Management Co. now owns 29,581 shares of the company’s stock worth $456,000 after purchasing an additional 902 shares in the last quarter. Finally, Nwam LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.1% in the 4th quarter. Nwam LLC now owns 30,083 shares of the company’s stock worth $464,000 after purchasing an additional 915 shares in the last quarter. 67.21% of the stock is currently owned by institutional investors and hedge funds.

TEVA has been the topic of several research reports. HSBC set a $12.00 price objective on Teva Pharmaceutical Industries and gave the stock a “sell” rating in a report on Tuesday, February 5th. ValuEngine downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 14th. Credit Suisse Group reduced their price objective on Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, February 14th. Finally, UBS Group initiated coverage on Teva Pharmaceutical Industries in a report on Thursday, March 7th. They set a “buy” rating and a $22.00 price objective on the stock. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus target price of $21.33.

ILLEGAL ACTIVITY WARNING: “Stock Traders Buy Large Volume of Teva Pharmaceutical Industries Call Options (TEVA)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/stock-traders-buy-large-volume-of-teva-pharmaceutical-industries-call-options-teva/2920839.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Straddles

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.